Diethyl-[(5-phenylpyridin-2-yl)methyl]phosphonate | 1256607-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Diethyl-[(5-phenylpyridin-2-yl)methyl]phosphonate
• 英文别名: 2-(diethoxyphosphorylmethyl)-5-phenylpyridine
• CAS: 1256607-06-3
• 化学式: C₁₆H₂₀NO₃P
• 分子量: 305.313
• InChiKey: NGGOLMVRQYVPFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3R,3aS,4S,5R,6S,7aR)-5-ethyl-3,6-dimethyl-1-oxo-3a,4,5,6,7,7a-hexahydro-3H-2-benzofuran-4-carbaldehyde 、 Diethyl-[(5-phenylpyridin-2-yl)methyl]phosphonate 在 titanium(IV) isopropylate 、 lithium hexamethyldisilazane 作用下， 生成 (3R,3aS,4S,5R,6S,7aR)-5-ethyl-3,6-dimethyl-4-[(E)-2-(5-phenylpyridin-2-yl)ethenyl]-3a,4,5,6,7,7a-hexahydro-3H-2-benzofuran-1-one
  参考文献：
  名称：

  Discovery of nor-seco himbacine analogs as thrombin receptor antagonists

  摘要：

  Discovery of a novel nor-seco himbacine analog as potent thrombin receptor (PAR-1) antagonist is described. Despite low plasma level, these new analogs showed excellent ex vivo efficacy in the monkey platelet aggregation assay. A potent hydroxy metabolite generated in vivo was identified as the agent responsible for the ex vivo efficacy. Following this discovery, the metabolite series was optimized to obtain analogs that showed very good ex vivo efficacy along with excellent pharmacokinetic profile in c. monkey. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.138
• 作为产物：
  描述：

  (5-溴吡啶-2-基)甲基磷酸二乙酯 、 苯硼酸 在 四(三苯基膦)钯 碳酸氢钠 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 2.0h， 以50%的产率得到Diethyl-[(5-phenylpyridin-2-yl)methyl]phosphonate
  参考文献：
  名称：

  Substituted piperidines

  摘要：

  本发明涉及新型取代哌啶，其制备方法，以及其用于治疗和/或预防疾病以及用于制备用于治疗和/或预防疾病的药物，特别是心血管疾病和肿瘤疾病。

  公开号：

  US20120142690A1

文献信息

• Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine
  申请人：Chackalamannil Samuel

  公开号：US20080085923A1

  公开（公告）日：2008-04-10

  Multiple stereoisomers of the heterocyclic-substituted tricyclics of the formula: or a pharmaceutically acceptable salt, solvate, or ester of said compound wherein R and the stereochemistry are illustrated in the structural formulas herein are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

  公开了异环取代的三环化合物的多个立体异构体的化学式：或者其药学上可接受的盐、溶剂合物或酯，其中R和立体化学在此处的结构式中有所示，以及含有它们的药物组合物和通过给药这些化合物治疗与血栓形成、动脉粥样硬化、再狭窄、高血压、心绞痛、心律失常、心力衰竭和癌症相关的疾病的方法。还声明了与其他心血管药物的联合治疗。
• NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY
  申请人：Song Yongcheng

  公开号：US20130065857A1

  公开（公告）日：2013-03-14

  The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particular embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.

  本发明通常涉及特定的抗微生物治疗方法和组合物。在特定实施例中，该组合物针对DXR。在具体实施例中，该组合物是电子不足的杂环环。
• [DE] SUBSTITUIERTE PIPERIDINE<br/>[EN] SUBSTITUTED PIPERIDINES<br/>[FR] PIPÉRIDINES SUBSTITUÉES
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2010136137A1

  公开（公告）日：2010-12-02

  Die Erfindung betrifft neue substituierte Piperidine, Verfahren zu ihrer Herstellung, ihre Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere von Herz-Kreislauf-Erkrankungen und von Tumorerkrankungen.
• Discovery of nor-seco himbacine analogs as thrombin receptor antagonists
  作者：Mariappan V. Chelliah、Samuel Chackalamannil、Yan Xia、Keith Eagen、William J. Greenlee、Ho-Sam Ahn、Jacqueline Agans-Fantuzzi、George Boykow、Yunsheng Hsieh、Matthew Bryant、Tze-Ming Chan、Madhu Chintala

  DOI：10.1016/j.bmcl.2012.01.138

  日期：2012.4

  Discovery of a novel nor-seco himbacine analog as potent thrombin receptor (PAR-1) antagonist is described. Despite low plasma level, these new analogs showed excellent ex vivo efficacy in the monkey platelet aggregation assay. A potent hydroxy metabolite generated in vivo was identified as the agent responsible for the ex vivo efficacy. Following this discovery, the metabolite series was optimized to obtain analogs that showed very good ex vivo efficacy along with excellent pharmacokinetic profile in c. monkey. (C) 2012 Elsevier Ltd. All rights reserved.
• Substituted piperidines
  申请人：Heimbach Dirk

  公开号：US20120142690A1

  公开（公告）日：2012-06-07

  The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.

  本发明涉及新型取代哌啶，其制备方法，以及其用于治疗和/或预防疾病以及用于制备用于治疗和/或预防疾病的药物，特别是心血管疾病和肿瘤疾病。